Clinical Trials Logo

Erdheim-Chester Disease clinical trials

View clinical trials related to Erdheim-Chester Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05092815 Active, not recruiting - Clinical trials for Langerhans Cell Histiocytosis

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Start date: December 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).

NCT ID: NCT02523040 Active, not recruiting - Clinical trials for Langerhans Cell Histiocytosis (LCH)

A Study of Lenalidomide for Adult Histiocyte Disorders

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).

NCT ID: NCT02285582 Active, not recruiting - Clinical trials for Juvenile Xanthogranuloma (JXG)

International Rare Histiocytic Disorders Registry (IRHDR)

IRHDR
Start date: October 2014
Phase:
Study type: Observational [Patient Registry]

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.

NCT ID: NCT01552434 Active, not recruiting - Malignant Neoplasm Clinical Trials

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Start date: March 16, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.